Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Anika Therapeutics (ANIK) over the last 12 years, with Q3 2025 value amounting to $22.2 million.

  • Anika Therapeutics' Short-term Investments fell 2175.83% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year decrease of 2175.83%. This contributed to the annual value of $23.6 million for FY2024, which is 1049.32% down from last year.
  • Anika Therapeutics' Short-term Investments amounted to $22.2 million in Q3 2025, which was down 2175.83% from $24.0 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Short-term Investments high stood at $36.7 million for Q2 2023, and its period low was $22.0 million during Q1 2025.
  • Over the past 5 years, Anika Therapeutics' median Short-term Investments value was $30.2 million (recorded in 2021), while the average stood at $29.7 million.
  • As far as peak fluctuations go, Anika Therapeutics' Short-term Investments surged by 109324.27% in 2021, and later crashed by 3145.56% in 2025.
  • Over the past 5 years, Anika Therapeutics' Short-term Investments (Quarter) stood at $29.8 million in 2021, then grew by 16.03% to $34.6 million in 2022, then decreased by 23.87% to $26.4 million in 2023, then decreased by 10.49% to $23.6 million in 2024, then dropped by 5.96% to $22.2 million in 2025.
  • Its last three reported values are $22.2 million in Q3 2025, $24.0 million for Q2 2025, and $22.0 million during Q1 2025.